GP40071 + NovoRapid® Penfill®
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes
Conditions
Diabetes, Diabetes Mellitus, Type 1
Trial Timeline
Jun 3, 2019 → Jan 21, 2020
NCT ID
NCT04079413About GP40071 + NovoRapid® Penfill®
GP40071 + NovoRapid® Penfill® is a phase 3 stage product being developed by GEROPHARM for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT04079413. Target conditions include Diabetes, Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04079413 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes